Cargando…

P045. OnabotulinumtoxinA: long term treatment for chronic migraine with medication overuse

Detalles Bibliográficos
Autores principales:	Guerzoni, Simona, Cainazzo, Maria Michela, Pini, Luigi Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715028/ https://www.ncbi.nlm.nih.gov/pubmed/28132205 http://dx.doi.org/10.1186/1129-2377-16-S1-A183

Ejemplares similares

Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2017)

Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy
por: Guerzoni, Simona, et al.
Publicado: (2018)

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients without medication overuse
por: Diener, HC, et al.
Publicado: (2013)

OnabotulinumtoxinA: Still the Present for Chronic Migraine
por: Baraldi, Carlo, et al.
Publicado: (2023)

OnabotulinumtoxinA: An Effective Tool in the Therapeutic Arsenal for Chronic Migraine With Medication Overuse
por: Caronna, Edoardo, et al.
Publicado: (2018)

Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuse
por: Ahmed, Fayyaz, et al.
Publicado: (2015)

Reply: OnabotulinumtoxinA should be considered in medication overuse withdrawal in patients with chronic migraine
por: Pijpers, Judith A, et al.
Publicado: (2020)

P054. Chronic migraine and onabotulinumtoxinA: results from clinical practice
por: Paolucci, Matteo, et al.
Publicado: (2015)

OnabotulinumtoxinA injections for the pain relief and long-term symptom control in a patient with hemiplegic migraine: case study
por: Dhawan, P, et al.
Publicado: (2013)

Chronic Migraine and Medication Overuse Headache Worsening After OnabotulinumtoxinA Withdrawn Due to the Severe Acute Respiratory Syndrome-Coronavirus-2 Pandemic
por: Baraldi, Carlo, et al.
Publicado: (2021)

P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatment
por: Rossi, Eleonora, et al.
Publicado: (2015)

P058. Refractory chronic migraine, fatigue and OnabotulinumtoxinA: a clinic setting experience
por: Baldacci, Filippo, et al.
Publicado: (2015)

Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment
por: Guerzoni, Simona, et al.
Publicado: (2016)

P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine
por: Negro, Andrea, et al.
Publicado: (2015)

Exploration of candidate serum biomarkers potentially related to the chronic pain condition in Medication–overuse headache
por: Pellesi, Lanfranco, et al.
Publicado: (2019)

OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all 5 treatment cycles in PREEMPT
por: Aurora, SK, et al.
Publicado: (2013)

The percent of chronic migraine patients who responded to onabotulinumtoxinA treatment per treatment cycle in the PREEMPT clinical program
por: Silberstein, S, et al.
Publicado: (2013)

P053. An Italian study on the actual cost/benefit of onabotulinumtoxinA (BT-A) in chronic migraine: preliminary results
por: Petolicchio, Barbara, et al.
Publicado: (2015)

Cognitive effects of onabotulinumtoxinA in chronic migraine
por: Ho, Susan, et al.
Publicado: (2020)

Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial
por: Pini, Luigi Alberto, et al.
Publicado: (2012)

Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
por: Parrales Bravo, Franklin, et al.
Publicado: (2019)

OnabotulinumtoxinA for chronic migraine treatment: 75% responder analysis from double-blind, randomized, placebo-controlled phase of PREEMPT
por: Dodick, D, et al.
Publicado: (2013)

P025. Two-year follow-up with OnabotulinumtoxinA for chronic migraine: a real life evaluation of 113 patients
por: Santoro, Antonio, et al.
Publicado: (2015)

Triptan efficacy does not predict onabotulinumtoxinA efficacy but improves with onabotulinumtoxinA response in chronic migraine patients
por: Eren, Ozan E., et al.
Publicado: (2020)

Galcanezumab for the treatment of chronic migraine and medication overuse headache: Real‐world clinical evidence in a severely impaired patient population
por: Guerzoni, Simona, et al.
Publicado: (2023)

Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Russell, Michael Bjørn
Publicado: (2011)

OnabotulinumtoxinA for chronic migraine: a critical appraisal
por: Gooriah, Rubesh, et al.
Publicado: (2015)

OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

Adult Abdominal Migraine Improved by OnabotulinumtoxinA Injections
por: Hermanowicz, Neal
Publicado: (2021)

OnabotulinumtoxinA in chronic migraine: is the response dose dependent?
por: Zandieh, Ali, et al.
Publicado: (2022)

Safety of OnabotulinumtoxinA in the [management of] chronic migraine in pregnancy
por: Smirnoff, Liza
Publicado: (2022)

OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study
por: Negro, Andrea, et al.
Publicado: (2015)

A Single-Group Study on the Effect of OnabotulinumtoxinA in Patients with Chronic Migraine Associated with Medication Overuse Headache: Pain Catastrophizing Plays a Role
por: Grazzi, Licia, et al.
Publicado: (2023)

Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study
por: Blumenfeld, Andrew M., et al.
Publicado: (2018)

Reply: Clinical trials on onabotulinumtoxinA for the treatment of chronic migraine
por: Aurora, Sheena, et al.
Publicado: (2011)

Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans
por: Byun, Jung-Ick, et al.
Publicado: (2017)

Correction to: OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine
por: Frampton, James E., et al.
Publicado: (2018)

OnabotulinumtoxinA in Chronic Migraine: A Profile of Its Use
por: Frampton, James E.
Publicado: (2020)

Real Life Data on OnabotulinumtoxinA for Treatment of Chronic Migraine in Pediatric Age
por: Papetti, Laura, et al.
Publicado: (2023)

Long-Term Safety and Tolerability of OnabotulinumtoxinA Treatment in Patients with Chronic Migraine: Results of the COMPEL Study
por: Winner, Paul K., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_cu3jmc22hpt0889fa5lpfsnj77